$ARRYArray BioPharma initiated with an Overweight at Cantor FitzgeraldCantor Fitzgerald analyst Varun Kumar started Array BioPharma with an Overweight rating and $30 price target. The stock currently trades at a "significant discount" as its lead asset, Mektovi plus Braftovi, still appears underappreciated by investors, Kumar tells investors in a research note. The analyst believes Array's MEK/BRAFi combination has a "best-in-class" profile and is well positioned commercially in BRAF-mutant melanoma and clinically in BRAF-mutant colorectal cancer.Read more at: (source)https://thefly.com/landingPage...Array BioPharma price target raised to $28 from $25 at Piper JaffrayPiper Jaffray analyst Edward Tenthoff raised his price target for Array BioPharma to $28 after the company reported initial median overall survival data from the Phase III Beacon trial for previously treated BRAF-mutant colorectal cancer. Mektovi, Braftovi plus Erbitux achieved median overall survival of 15.3 months versus historical expectations of only six months, Tenthoff tells investors in a research note. These data further strengthen confidence in positive interim Beacon results in the first half of 2019, which could form the basis for accelerated approval next year, says the analyst. He reiterates an Overweight rating on Array BioPharma.Read more at: (source)https://thefly.com/landingPage...* This stock has been on our trading list for a while now. Will continue to look for trades in this name. * Tiger's Take: "This one has also been rumored to be a buy-out/takeover candidate." $ARRY, Array BioPharma Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.